Abstract
Rational Infection with the SARS-CoV2 virus is associated with elevated neutrophil counts. Evidence of neutrophil dysfunction in COVID-19 is based predominantly on transcriptomics or single functional assays. Cell functions are interwoven pathways, and so understanding the effect of COVID-19 across the spectrum of neutrophil function may identify tractable therapeutic targets.
Objectives Examine neutrophil phenotype and functional capacity in COVID-19 patients versus age-matched controls (AMC)
Methods Isolated neutrophils from 41 hospitalised, non-ICU COVID-19 patients and 23 AMC underwent ex vivo analyses for migration, bacterial phagocytosis, ROS generation, NET formation (NETosis) and cell surface receptor expression. DNAse 1 activity was measured, alongside circulating levels of cfDNA, MPO, VEGF, IL-6 and sTNFRI. All measurements were correlated to clinical outcome. Serial sampling on day 3-5 post hospitalisation were also measured.
Results Compared to AMC, COVID-19 neutrophils demonstrated elevated transmigration (p=0.0397) and NETosis (p=0.0366), but impaired phagocytosis (p=0.0236) associated with impaired ROS generation (p<0.0001). Surface expression of CD54 (p<0.0001) and CD11c (p=0.0008) was significantly increased and CD11b significantly decreased (p=0.0229) on COVID-19 patient neutrophils. COVID-19 patients showed increased systemic markers of NETosis including increased cfDNA (p=0.0153) and impaired DNAse activity (p<0.0.001). MPO (p<0.0001), VEGF (p<0.0001), TNFRI (p<0.0001) and IL-6 (p=0.009) were elevated in COVID-19, which positively correlated with disease severity by 4C score.
Conclusion COVID-19 is associated with neutrophil dysfunction across all main effector functions, with altered phenotype, elevated migration, impaired antimicrobial responses and elevated NETosis. These changes represent a clear mechanism for tissue damage and highlight that targeting neutrophil function may help modulate COVID-19 severity.
Competing Interest Statement
Grant funding for research but no other competing interest: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: all authors had financial support from Medical Research Council for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
OST/DT/DP; Birmingham Health partners, KBRB/ES; Alpha One Foundation (617303), JH; National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre, ES/KYP; British Lung Foundation (PPRG16), DT/AS/ES/FSG; Dunhill trust (RTF1906\86), ES; Health Data Research-UK, DT/DP; Health Technology Assessment, DT/AS/ES; Health Technology Assessment (NIHR129593), DT/AS/ES; Medical Research Council (MR/L002736/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
19/WA/0299 and 20/WA/0092 approved by the West Midlands - Solihull research ethics committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* joint first author
# joint senior author
This article has an online supplement.
Sources of funding: OST/DT/DP; Birmingham Health partners, KBRB/ES; Alpha One Foundation (617303), JH; National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre, ES/KYP; British Lung Foundation (PPRG16), DT/AS/ES/FSG; Dunhill trust (RTF1906\86), ES; Health Data Research-UK, DT/DP; Health Technology Assessment, DT/AS/ES; Health Technology Assessment (NIHR129593), DT/AS/ES; Medical Research Council (MR/L002736/1).
Data Availability
None
